Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Terpos E, et al. Among authors: croucher pi. Br J Haematol. 2006 Dec;135(5):688-92. doi: 10.1111/j.1365-2141.2006.06356.x. Br J Haematol. 2006. PMID: 17107351 Free article.
Myeloma bone disease and proteasome inhibition therapies.
Terpos E, Sezer O, Croucher P, Dimopoulos MA. Terpos E, et al. Blood. 2007 Aug 15;110(4):1098-104. doi: 10.1182/blood-2007-03-067710. Epub 2007 May 9. Blood. 2007. PMID: 17494860 Free article. Review.
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K. Menu E, et al. Int J Cancer. 2007 Oct 15;121(8):1857-61. doi: 10.1002/ijc.22845. Int J Cancer. 2007. PMID: 17546599
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. Terpos E, et al. Leukemia. 2008 Dec;22(12):2247-56. doi: 10.1038/leu.2008.235. Epub 2008 Sep 4. Leukemia. 2008. PMID: 18769451 Clinical Trial.
182 results